Johannes Gerardus Chri Schikan Sells 30,712 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares in the company, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $241,424.40.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Price Performance

PHVS stock opened at $33.86 on Friday. The firm has a market cap of $2.21 billion, a PE ratio of -10.65 and a beta of -2.34. Pharvaris N.V. has a 12 month low of $17.05 and a 12 month high of $35.90. The firm has a 50 day simple moving average of $31.00 and a 200 day simple moving average of $28.28.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts expect that Pharvaris N.V. will post -3.2 earnings per share for the current year.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, reinforcing a favorable analyst view of the company’s outlook. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
• Positive Sentiment: PHVS recently set a new 1-year high, showing strong momentum and suggesting investors have been optimistic heading into this period. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
• Neutral Sentiment: Insider trading activity was heavy over June 29-30, with Director Johannes Gerardus Chri Schikan and insider Anne Lesage selling shares at prices around $35.05-$35.49. The sales may create some concern about near-term sentiment, but they do not necessarily indicate a change in the company’s fundamentals. SEC insider filing

Institutional Trading of Pharvaris

Hedge funds have recently modified their holdings of the business. California State Teachers Retirement System increased its stake in shares of Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after acquiring an additional 520 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the fourth quarter valued at about $35,000. Public Employees Retirement System of Ohio grew its stake in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PHVS shares. Citizens Jmp reduced their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research note on Tuesday, June 16th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective on the stock. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $49.64.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.